240 related articles for article (PubMed ID: 27109624)
1. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET
Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624
[TBL] [Abstract][Full Text] [Related]
2. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H
Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071
[TBL] [Abstract][Full Text] [Related]
3. The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.
Ripley TL; Sanchez-Roige S; Bullmore ET; Mugnaini M; Maltby K; Miller SR; Wille DR; Nathan P; Stephens DN
Psychopharmacology (Berl); 2015 Sep; 232(18):3431-41. PubMed ID: 26141191
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans.
Rabiner EA; Beaver J; Makwana A; Searle G; Long C; Nathan PJ; Newbould RD; Howard J; Miller SR; Bush MA; Hill S; Reiley R; Passchier J; Gunn RN; Matthews PM; Bullmore ET
Mol Psychiatry; 2011 Aug; 16(8):826-35, 785. PubMed ID: 21502953
[TBL] [Abstract][Full Text] [Related]
5. The Novel μ-Opioid Receptor Antagonist GSK1521498 Decreases Both Alcohol Seeking and Drinking: Evidence from a New Preclinical Model of Alcohol Seeking.
Giuliano C; Goodlett CR; Economidou D; García-Pardo MP; Belin D; Robbins TW; Bullmore ET; Everitt BJ
Neuropsychopharmacology; 2015 Dec; 40(13):2981-92. PubMed ID: 26044906
[TBL] [Abstract][Full Text] [Related]
6. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
[TBL] [Abstract][Full Text] [Related]
7. The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects.
Ziauddeen H; Nathan PJ; Dodds C; Maltby K; Miller SR; Waterworth D; Song K; Warren L; Hosking L; Zucchetto M; Bush M; Johnson LV; Sarai B; Mogg K; Bradley BP; Richards DB; Fletcher PC; Bullmore ET
J Clin Pharmacol; 2013 Oct; 53(10):1078-90. PubMed ID: 23934621
[TBL] [Abstract][Full Text] [Related]
8. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Ray LA; Hutchison KE
Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating.
Giuliano C; Robbins TW; Nathan PJ; Bullmore ET; Everitt BJ
Neuropsychopharmacology; 2012 Nov; 37(12):2643-52. PubMed ID: 22805601
[TBL] [Abstract][Full Text] [Related]
10. Increased ethanol drinking in "humanized" mice expressing the mu opioid receptor A118G polymorphism are mediated through sex-specific mechanisms.
Henderson-Redmond AN; Lowe TE; Tian XB; Morgan DJ
Brain Res Bull; 2018 Apr; 138():12-19. PubMed ID: 28780411
[TBL] [Abstract][Full Text] [Related]
11. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
[TBL] [Abstract][Full Text] [Related]
12. The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours.
Kelly E; Mundell SJ; Sava A; Roth AL; Felici A; Maltby K; Nathan PJ; Bullmore ET; Henderson G
Psychopharmacology (Berl); 2015 Jan; 232(1):305-14. PubMed ID: 24973897
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial.
Ray LA; Green R; Roche DJO; Bujarski S; Hartwell EE; Lim AC; Rohrbaugh T; Ghahremani D; Hutchison K; Miotto K
Alcohol Clin Exp Res; 2018 Mar; 42(3):613-623. PubMed ID: 29265379
[TBL] [Abstract][Full Text] [Related]
14. Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people.
Cambridge VC; Ziauddeen H; Nathan PJ; Subramaniam N; Dodds C; Chamberlain SR; Koch A; Maltby K; Skeggs AL; Napolitano A; Farooqi IS; Bullmore ET; Fletcher PC
Biol Psychiatry; 2013 May; 73(9):887-94. PubMed ID: 23245760
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
[TBL] [Abstract][Full Text] [Related]
16. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
Kranzler HR; Armeli S; Covault J; Tennen H
Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013
[TBL] [Abstract][Full Text] [Related]
17. Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects.
Ziauddeen H; Chamberlain SR; Nathan PJ; Koch A; Maltby K; Bush M; Tao WX; Napolitano A; Skeggs AL; Brooke AC; Cheke L; Clayton NS; Sadaf Farooqi I; O'Rahilly S; Waterworth D; Song K; Hosking L; Richards DB; Fletcher PC; Bullmore ET
Mol Psychiatry; 2013 Dec; 18(12):1287-93. PubMed ID: 23147384
[TBL] [Abstract][Full Text] [Related]
18. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
[TBL] [Abstract][Full Text] [Related]
19. Increased mesolimbic cue-reactivity in carriers of the mu-opioid-receptor gene OPRM1 A118G polymorphism predicts drinking outcome: a functional imaging study in alcohol dependent subjects.
Bach P; Vollsta Dt-Klein S; Kirsch M; Hoffmann S; Jorde A; Frank J; Charlet K; Beck A; Heinz A; Walter H; Sommer WH; Spanagel R; Rietschel M; Kiefer F
Eur Neuropsychopharmacol; 2015 Aug; 25(8):1128-35. PubMed ID: 25937240
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
